FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Diana Donnelly-Roberts

Research Profile

Living Beings

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Xenia Beebe; Janel M Boyce-Rustay; Daria Darczak; Diana L Donnelly-Roberts; Pamela Franklin; Erica Gomez; Rodger F Henry; Richard Janis; Michael F Jarvis; Karen Kage; Kennan Marsh; Ivan Milicic; Marian T Namovic; Wende Niforatos; Gricelda Simler; Andrew O Stewart; Carol S Surowy; Andrew Swensen; Timothy A Vortherms; Jill M Wetter; Chengmin Zhong; Chang Z Zhu; Scott Baker; Victoria E Scott
Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.
Marian T Namovic; Michael F Jarvis; Diana L Donnelly-Roberts
High throughput functional assays for P2X receptors.
Timothy A Vortherms; Di Zhang; Carol S Surowy; Andrew M Swensen; Rama Thimmapaya; C Brent Putman; Diana L Donnelly-Roberts; Richard S Janis; Michael F Jarvis; James T Limberis; Ruth L Martin; Marian T Namovic; Torben R Neelands; Wende Niforatos; Victoria E Scott
Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Diana Donnelly-Roberts (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Xenia Beebe; Janel M Boyce-Rustay; Daria Darczak; Diana L Donnelly-Roberts; Pamela Franklin; Erica Gomez; Rodger F Henry; Richard Janis; Michael F Jarvis; Karen Kage; Kennan Marsh; Ivan Milicic; Marian T Namovic; Wende Niforatos; Gricelda Simler; Andrew O Stewart; Carol S Surowy; Andrew Swensen; Timothy A Vortherms; Jill M Wetter; Chengmin Zhong; Chang Z Zhu; Scott Baker; Victoria E Scott
Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.
Bioorganic & medicinal chemistry 2012;20(13):4128-39.
2012: Marian T Namovic; Michael F Jarvis; Diana L Donnelly-Roberts
High throughput functional assays for P2X receptors.
Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] 2012;Chapter 9():Unit 9.15..
2011: Timothy A Vortherms; Di Zhang; Carol S Surowy; Andrew M Swensen; Rama Thimmapaya; C Brent Putman; Diana L Donnelly-Roberts; Richard S Janis; Michael F Jarvis; James T Limberis; Ruth L Martin; Marian T Namovic; Torben R Neelands; Wende Niforatos; Victoria E Scott
Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2011;60(7):683-93.
2011: Arturo Perez-Medrano; Diana L Donnelly-Roberts; Alan S Florjancic; Derek W Nelson; Tongmei Li; Marian T Namovic; Sridhar Peddi; Connie R Faltynek; Michael F Jarvis; William A Carroll
Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) antagonists.
Bioorganic & medicinal chemistry letters 2011;21(11):3297-300.
2009: Prisca Honore; Diana L Donnelly-Roberts; Marian T Namovic; Chengmin Zhong; Carrie Wade; Prasant Chandran; Chang Zhu; William Carroll; Arturo Perez-Medrano; Yoichiro Iwakura; Michael F Jarvis
The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice.
Behavioural brain research 2009;204(1):77-81.
2009: Diana L Donnelly-Roberts; Marian T Namovic; Ping Han; Michael F Jarvis
Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors.
British journal of pharmacology 2009;157(7):1203-14.
2009: Arturo Perez-Medrano; Diana L Donnelly-Roberts; Prisca Honore; Gin C Hsieh; Marian T Namovic; Sridhar Peddi; Qi Shuai; Ying Wang; Connie R Faltynek; Michael F Jarvis; William A Carroll
Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain.
Journal of medicinal chemistry 2009;52(10):3366-76.
2009: William A Carroll; Diana L Donnelly-Roberts; Michael F Jarvis
Selective P2X(7) receptor antagonists for chronic inflammation and pain.
Purinergic signalling 2009;5(1):63-73.
2009: Diana L Donnelly-Roberts; Marian T Namovic; Bruce W Surber; Srirajan X Vaidyanathan; Arturo Perez-Medrano; Ying Wang; William A Carroll; Michael F Jarvis
[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.
Neuropharmacology 2009;56(1):223-9.
2008: Patrick Betschmann; Brian Bettencourt; Diana L Donnelly-Roberts; Michael Friedman; Jonathan George; Gavin Hirst; Nathan Josephsohn; Donald Konopacki; Biqin Li; John Maull; Michael J Morytko; Nigel Stjohn Moore; Marian T Namovic; Paul Rafferty; Jose-Andres Salmeron-Garcia; Edit Tarcsa; Lu Wang; Kevin Woller
Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists.
Bioorganic & medicinal chemistry letters 2008;18(14):3848-51.
2008: Derek W Nelson; Kathy A Sarris; Douglas Kalvin; Marian T Namovic; George Grayson; Diana L Donnelly-Roberts; Richard Harris; Prisca Honore; Michael F Jarvis; Connie R Faltynek; William A Carroll
Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists.
Journal of medicinal chemistry 2008;51(10):3030-4.
2008: Alan S Florjancic; Sridhar Peddi; Arturo Perez-Medrano; Biqin Li; Marian T Namovic; George Grayson; Diana L Donnelly-Roberts; Michael F Jarvis; William A Carroll
Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists.
Bioorganic & medicinal chemistry letters 2008;18(6):2089-92.
2008: Michael J Morytko; Patrick Betschmann; Kevin Woller; Anna Ericsson; Haipeng Chen; Diana L Donnelly-Roberts; Marian T Namovic; Michael F Jarvis; William A Carroll; Paul Rafferty
Synthesis and in vitro activity of N'-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonists.
Bioorganic & medicinal chemistry letters 2008;18(6):2093-6.
2008: Diana L Donnelly-Roberts; Steve McGaraughty; Char-Chang Shieh; Prisca Honore; Michael F Jarvis
Painful purinergic receptors.
The Journal of pharmacology and experimental therapeutics 2008;324(2):409-15.
2007: William A Carroll; Douglas Kalvin; Arturo Perez-Medrano; Alan S Florjancic; Ying Wang; Diana L Donnelly-Roberts; Marian T Namovic; George Grayson; Prisca Honoré; Michael F Jarvis
Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists.
Bioorganic & medicinal chemistry letters 2007;17(14):4044-8.
2007: Diana L Donnelly-Roberts; Michael F Jarvis
Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.
British journal of pharmacology 2007;151(5):571-9.
2007: Steve McGaraughty; Katharine L Chu; Marian T Namovic; Diana L Donnelly-Roberts; Richard R Harris; Xu-Feng Zhang; Char-Chang Shieh; Carol T Wismer; Chang Z Zhu; Donna M Gauvin; Adebola Fabiyi; Prisca Honore; Robert J Gregg; Michael E Kort; D W Nelson; William A Carroll; Kennan Marsh; Connie R Faltynek; Michael F Jarvis
P2X7-related modulation of pathological nociception in rats.
Neuroscience 2007;146(4):1817-28.
2006: Meena V Patel; Teodozyi Kolasa; Kathleen H Mortell; Mark A Matulenko; Ahmed A Hakeem; Jeffrey J Rohde; Sherry L Nelson; Marlon D Cowart; Masaki Nakane; Loan N Miller; Marie E Uchic; Marc A Terranova; Odile F El-Kouhen; Diana L Donnelly-Roberts; Marian T Namovic; Peter R Hollingsworth; Renjie Chang; Brenda Martino; Jill M Wetter; Kennan Marsh; Ruth Martin; John F Darbyshire; Gary Gintant; Gin C Hsieh; Robert B Moreland; James P Sullivan; Jorge D Brioni; Andrew O Stewart
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Journal of medicinal chemistry 2006;49(25):7450-65.
2006: Prisca Honore; Diana L Donnelly-Roberts; Marian T Namovic; Gin C Hsieh; Chang Z Zhu; Joe Mikusa; Gricelda Hernandez; Chengmin Zhong; Donna M Gauvin; Prasant Chandran; Richard Harris; Arturo Perez Medrano; William Carroll; Kennan Marsh; James P Sullivan; Connie R Faltynek; Michael F Jarvis
A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat.
The Journal of pharmacology and experimental therapeutics 2006;319(3):1376-85.
2006: Teodozyi Kolasa; Mark A Matulenko; Ahmed A Hakeem; Meena V Patel; Kathleen H Mortell; Pramila Bhatia; Rodger Henry; Masaki Nakane; Gin C Hsieh; Marc A Terranova; Marie E Uchic; Loan N Miller; Renjie Chang; Diana L Donnelly-Roberts; Marian T Namovic; Peter R Hollingsworth; Brenda Martino; Odile F El-Kouhen; Kennan Marsh; Jill M Wetter; Robert B Moreland; Jorge D Brioni; Andrew O Stewart
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Journal of medicinal chemistry 2006;49(17):5093-109.
2006: Derek W Nelson; Robert J Gregg; Michael E Kort; Arturo Perez-Medrano; Eric A Voight; Ying Wang; George Grayson; Marian T Namovic; Diana L Donnelly-Roberts; Wende Niforatos; Prisca Honore; Michael F Jarvis; Connie R Faltynek; William A Carroll
Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.
Journal of medicinal chemistry 2006;49(12):3659-66.
2006: Lynne E Rueter; Diana L Donnelly-Roberts; Peter Curzon; Clark A Briggs; David J Anderson; Robert S Bitner
A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor.
CNS drug reviews 2006;12(2):100-12.
2005: Masaki Nakane; Marlon D Cowart; Gin C Hsieh; Loan Miller; Marie E Uchic; Renjie Chang; Marc A Terranova; Diana L Donnelly-Roberts; Marian T Namovic; Thomas R Miller; Jill M Wetter; Kennan Marsh; Andrew O Stewart; Jorge D Brioni; Robert B Moreland
2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
Neuropharmacology 2005;49(1):112-21.
2005: Y-W Chen; Diana L Donnelly-Roberts; Marian T Namovic; Gary Gintant; Bryan Cox; Michael F Jarvis; Richard R Harris
Pharmacological characterization of P2X7 receptors in rat peritoneal cells.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2005;54(3):119-26.
2004: Monique R Adams; Arthur L Nikkel; Diana L Donnelly-Roberts; Andrew T Watt; Joseph F Johnston; Lex M Cowsert; Mandeline Butler; Paul Kroeger; Leigh Frost; Peter Curzon; Michael W Decker; Robert S Bitner
In vitro and in vivo effects of an alpha3 neuronal nicotinic acetylcholine receptor antisense oligonucleotide.
Brain research. Molecular brain research 2004;129(1-2):67-79.
2004: Mark A Matulenko; Bruce W Surber; Leimin Fan; Teodozyi Kolasa; Masaki Nakane; Marc A Terranova; Marie E Uchic; Loan N Miller; Renjie Chang; Diana L Donnelly-Roberts; Marian T Namovic; Robert B Moreland; Jorge D Brioni; Andrew O Stewart
Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand.
Bioorganic & medicinal chemistry letters 2004;14(20):5095-8.
2004: Robert B Moreland; Masaki Nakane; Diana L Donnelly-Roberts; Loan N Miller; Renjie Chang; Marie E Uchic; Marc A Terranova; Earl J Gubbins; Rosalind J Helfrich; Marian T Namovic; Odile F El-Kouhen; Jeffrey N Masters; Jorge D Brioni
Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).
Biochemical pharmacology 2004;68(4):761-72.
2004: Marlon D Cowart; Steven P Latshaw; Pramila Bhatia; Jerome F Daanen; Jeffrey J Rohde; Sherry L Nelson; Meena Patel; Teodozyi Kolasa; Masaki Nakane; Marie E Uchic; Loan N Miller; Marc A Terranova; Renjie Chang; Diana L Donnelly-Roberts; Marian T Namovic; Peter R Hollingsworth; Brenda Martino; James J Lynch; James P Sullivan; Gin C Hsieh; Robert B Moreland; Jorge D Brioni; Andrew O Stewart
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.
Journal of medicinal chemistry 2004;47(15):3853-64.
2004: Mark A Matulenko; Ahmed A Hakeem; Teodozyi Kolasa; Masaki Nakane; Marc A Terranova; Marie E Uchic; Loan N Miller; Renjie Chang; Diana L Donnelly-Roberts; Marian T Namovic; Robert B Moreland; Jorge D Brioni; Andrew O Stewart
Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: selective dopamine D4 receptor agonists.
Bioorganic & medicinal chemistry 2004;12(13):3471-83.
2004: Jorge D Brioni; Robert B Moreland; Marlon D Cowart; Gin C Hsieh; Andrew O Stewart; Petter Hedlund; Diana L Donnelly-Roberts; Masaki Nakane; James J Lynch; Teodozyi Kolasa; James S Polakowski; Mark A Osinski; Kennan Marsh; Karl-Erik Andersson; James P Sullivan
Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(17):6758-63.
2004: Andrew O Stewart; Marlon D Cowart; Robert B Moreland; Steven P Latshaw; Mark A Matulenko; Pramila Bhatia; Xueqing Wang; Jerome F Daanen; Sherry L Nelson; Marc A Terranova; Marian T Namovic; Diana L Donnelly-Roberts; Loan N Miller; Masaki Nakane; James P Sullivan; Jorge D Brioni
Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.
Journal of medicinal chemistry 2004;47(9):2348-55.
2004: Diana L Donnelly-Roberts; Marian T Namovic; Connie R Faltynek; Michael F Jarvis
Mitogen-activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-induced pore formation in human THP-1 cells.
The Journal of pharmacology and experimental therapeutics 2004;308(3):1053-61.
2004: Lynne E Rueter; David J Anderson; Clark A Briggs; Diana L Donnelly-Roberts; Gary Gintant; Murali Gopalakrishnan; Nan-Horng Lin; Mark A Osinski; Glenn A Reinhart; Michael J Buckley; Ruth L Martin; Jeffrey S McDermott; Lee C Preusser; Terese R Seifert; Zhi Su; Bryan Cox; Michael W Decker; James P Sullivan
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.
CNS drug reviews 2004;10(2):167-82.
2004: Gin C Hsieh; Peter R Hollingsworth; Brenda Martino; Renjie Chang; Marc A Terranova; Alyssa B O'Neill; James J Lynch; Robert B Moreland; Diana L Donnelly-Roberts; Teodozyi Kolasa; Joe Mikusa; Jill M McVey; Kennan Marsh; James P Sullivan; Jorge D Brioni
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine.
The Journal of pharmacology and experimental therapeutics 2004;308(1):330-8.
2003: Sujatha M Gopalakrishnan; Robert B Moreland; James L Kofron; Rosalind J Helfrich; Earl J Gubbins; Jennifer McGowen; Jeffrey N Masters; Diana L Donnelly-Roberts; Jorge D Brioni; David J Burns; Usha Warrior
A cell-based microarrayed compound screening format for identifying agonists of G-protein-coupled receptors.
Analytical biochemistry 2003;321(2):192-201.
2000: Robert S Bitner; Arthur L Nikkel; Peter Curzon; Diana L Donnelly-Roberts; Pamela S Puttfarcken; Marian T Namovic; I C Jacobs; Michael D Meyer; Michael W Decker
Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat.
Brain research 2000;871(1):66-74.
1998: Mark W Holladay; Hao Bai; Y Li; Nan-Horng Lin; Jerome F Daanen; Keith B Ryther; JT Wasicak; J F Kincaid; Yun He; A M Hettinger; P Huang; David J Anderson; AW Bannon; Michael J Buckley; Jeffrey Campbell; Diana L Donnelly-Roberts; KL Gunther; DJ Kim; TA Kuntzweiler; James P Sullivan; Michael W Decker; Stephen P Arneric
Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.
Bioorganic & medicinal chemistry letters 1998;8(19):2797-802.
1998: Michael W Decker; Peter Curzon; Mark W Holladay; Arthur L Nikkel; Robert S Bitner; AW Bannon; Diana L Donnelly-Roberts; Pamela S Puttfarcken; TA Kuntzweiler; Clark A Briggs; Michael Williams; Stephen P Arneric
The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594.
Journal of physiology, Paris 1998;92(3-4):221-4.
1998: Diana L Donnelly-Roberts; Pamela S Puttfarcken; TA Kuntzweiler; Clark A Briggs; David J Anderson; Jeffrey Campbell; M Piattoni-Kaplan; David G McKenna; JT Wasicak; Mark W Holladay; Michael Williams; Stephen P Arneric
ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
The Journal of pharmacology and experimental therapeutics 1998;285(2):777-86.
1998: Mark W Holladay; JT Wasicak; Nan-Horng Lin; Yun He; Keith B Ryther; AW Bannon; Michael J Buckley; DJ Kim; Michael W Decker; David J Anderson; Jeffrey Campbell; TA Kuntzweiler; Diana L Donnelly-Roberts; M Piattoni-Kaplan; Clark A Briggs; Michael Williams; Stephen P Arneric
Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
Journal of medicinal chemistry 1998;41(4):407-12.
1998: Nan-Horng Lin; David Gunn; Y Li; Yun He; Hao Bai; Keith B Ryther; TA Kuntzweiler; Diana L Donnelly-Roberts; David J Anderson; Jeffrey Campbell; James P Sullivan; Stephen P Arneric; Mark W Holladay
Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.
Bioorganic & medicinal chemistry letters 1998;8(3):249-54.
1998: AW Bannon; Michael W Decker; Mark W Holladay; Peter Curzon; Diana L Donnelly-Roberts; Pamela S Puttfarcken; Robert S Bitner; A Diaz; A H Dickenson; Roger D Porsolt; Michael Williams; Stephen P Arneric
Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors.
Science (New York, N.Y.) 1998;279(5347):77-81.
1997: James P Sullivan; Diana L Donnelly-Roberts; Clark A Briggs; David J Anderson; Murali Gopalakrishnan; I C Xue; M Piattoni-Kaplan; Eduardo J Molinari; Jeffrey Campbell; David G McKenna; David Gunn; Nan-Horng Lin; Keith B Ryther; Yun He; Mark W Holladay; S Wonnacott; Michael Williams; Stephen P Arneric
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
The Journal of pharmacology and experimental therapeutics 1997;283(1):235-46.
1997: Pamela S Puttfarcken; Arlene M Manelli; Stephen P Arneric; Diana L Donnelly-Roberts
Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells.
Journal of neurochemistry 1997;69(3):930-8.
1997: Clark A Briggs; David J Anderson; Jorge D Brioni; Jerry J Buccafusco; Michael J Buckley; Jeffrey Campbell; Michael W Decker; Diana L Donnelly-Roberts; RL Elliott; Murali Gopalakrishnan; Mark W Holladay; Yu-Hua Hui; WJ Jackson; DJ Kim; Kennan Marsh; A O'Neill; Mark A Prendergast; Keith B Ryther; James P Sullivan; Stephen P Arneric
Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo.
Pharmacology, biochemistry, and behavior 1997;57(1-2):231-41.
1997: Nan-Horng Lin; David Gunn; Keith B Ryther; David Scott Garvey; Diana L Donnelly-Roberts; Michael W Decker; Jorge D Brioni; Michael J Buckley; A David Rodrigues; Kennan Marsh; David J Anderson; Jerry J Buccafusco; Mark A Prendergast; James P Sullivan; Michael Williams; Stephen P Arneric; Mark W Holladay
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.
Journal of medicinal chemistry 1997;40(3):385-90.
1996: James P Sullivan; Diana L Donnelly-Roberts; Clark A Briggs; David J Anderson; Murali Gopalakrishnan; M Piattoni-Kaplan; Jeffrey Campbell; David G McKenna; Eduardo J Molinari; A M Hettinger; David Scott Garvey; JT Wasicak; Mark W Holladay; Michael Williams; Stephen P Arneric
A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.
Neuropharmacology 1996;35(6):725-34.
1996: Diana L Donnelly-Roberts; I C Xue; Stephen P Arneric; James P Sullivan
In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418.
Brain research 1996;719(1-2):36-44.
1996: M A Abreo; Nan-Horng Lin; David Scott Garvey; David Gunn; A M Hettinger; JT Wasicak; P A Pavlik; Yvonne C Martin; Diana L Donnelly-Roberts; David J Anderson; James P Sullivan; Michael Williams; Stephen P Arneric; Mark W Holladay
Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.
Journal of medicinal chemistry 1996;39(4):817-25.
1996: Murali Gopalakrishnan; LM Monteggia; David J Anderson; Eduardo J Molinari; M Piattoni-Kaplan; Diana L Donnelly-Roberts; Stephen P Arneric; James P Sullivan
Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
The Journal of pharmacology and experimental therapeutics 1996;276(1):289-97.
1995: Murali Gopalakrishnan; B Buisson; E Touma; T Giordano; Jeffrey Campbell; I C Hu; Diana L Donnelly-Roberts; Stephen P Arneric; Daniel Bertrand; James P Sullivan
Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor.
European journal of pharmacology 1995;290(3):237-46.
1995: Diana L Donnelly-Roberts; Stephen P Arneric; James P Sullivan
Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists.
Biochemical and biophysical research communications 1995;213(2):657-62.
1995: Michael W Decker; David J Anderson; Jorge D Brioni; Diana L Donnelly-Roberts; C H Kang; Alyssa B O'Neill; M Piattoni-Kaplan; S Swanson; James P Sullivan
Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors.
European journal of pharmacology 1995;280(1):79-89.
1995: Stephen P Arneric; James P Sullivan; Michael W Decker; Jorge D Brioni; AW Bannon; Clark A Briggs; Diana L Donnelly-Roberts; R J Radek; Kennan Marsh; J Kyncl
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
Alzheimer disease and associated disorders 1995;9 Suppl 2():50-61.
1995: James P Sullivan; Michael W Decker; Diana L Donnelly-Roberts; Jorge D Brioni; AW Bannon; Mark W Holladay; David J Anderson; Clark A Briggs; Michael Williams; Stephen P Arneric
Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.
Proceedings of the Western Pharmacology Society 1995;38():127-30.
1994: James P Sullivan; Michael W Decker; Jorge D Brioni; Diana L Donnelly-Roberts; David J Anderson; AW Bannon; C H Kang; P Adams; M Piattoni-Kaplan; Michael J Buckley
(+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.
The Journal of pharmacology and experimental therapeutics 1994;271(2):624-31.
1994: Stephen P Arneric; James P Sullivan; Clark A Briggs; Diana L Donnelly-Roberts; David J Anderson; J L Raszkiewicz; M L Hughes; Evelyn Cadman; P Adams; David Scott Garvey
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
The Journal of pharmacology and experimental therapeutics 1994;270(1):310-8.